As of June 30, 2026, Cambium Bio Ltd carries a market capitalization of 11.75M, placing it among publicly traded companies globally. Its enterprise value stands at 10.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.75M |
| Enterprise Value | 10.79M |
Cambium Bio Ltd's next confirmed earnings release is scheduled for March 4, 2027.
| Earnings Date | 3/4/2027 |
As of June 30, 2026, Cambium Bio Ltd has 27.33M shares outstanding.
| Shares Outstanding | 27.33M |
These figures are as of June 30, 2026.
| PB Ratio | 4.94 |
| P/TBV Ratio | -166.86 |
As of June 30, 2026, Cambium Bio Ltd maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.30, indicating elevated leverage, while an interest coverage ratio of -349.91 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.95 |
| Quick Ratio | 0.93 |
| Debt / Equity | 6.30 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -349.91 |
Over the twelve months ended June 30, 2026, Cambium Bio Ltd posted a negative return on equity (ROE) of -194.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -116.06, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -194.37 |
| Return on Assets (ROA) | -116.06 |
As of the close on October 21, 2026, Cambium Bio Ltd's stock has declined approximately 6.25% over the past 52 weeks. The 50-day moving average sits at 0.44, while the 200-day moving average is 0.45.
| 52-Week Price Change | -6.25% |
| 50-Day Moving Average | 0.44 |
| 200-Day Moving Average | 0.45 |
These figures cover the twelve months ended June 30, 2026. EBITDA reached -4.81M, while operating income came in at -4.81M.
| Operating Income | -4.81M |
| Pretax Income | -4.10M |
| Net Income | -4.10M |
| EBITDA | -4.81M |
| EBIT | -4.81M |
| Earnings Per Share (EPS) | -0.17 |
As of June 30, 2026, Cambium Bio Ltd holds 1.12M in cash and equivalents against 149,804.00 in total debt, resulting in a net debt position of -966,363.00. Total book value stands at 2.38M, with working capital of -72,986.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.12M |
| Total Debt | 149,804.00 |
| Net Debt | -966,363.00 |
| Equity (Book Value) | 2.38M |
| Book Value Per Share | 0.09 |
| Working Capital | -72,986.00 |
These figures cover the twelve months ended June 30, 2026.
| Capital Expenditures | -2,638.00 |
These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -36.11, meaning Cambium Bio Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -36.11 |
Cambium Bio Ltd's most recent stock split took place on July 17, 2024 with a 100:1 split ratio.
| Last Split Date | 7/17/2024 |
| Split Ratio | 100:1 |
Already premium?